The FDA formally removed semaglutide from its drug shortage list in late 2025, triggering a compliance deadline that forced the majority of compounding pharmacies to stop producing copies of Novo Nordisk's Ozempic and Wegovy. As of April 2026, most large telehealth platforms have suspended new compounded semaglutide prescriptions — but a meaningful subset continues to ship under two surviving legal pathways, and patients already in mid-course treatment are navigating a fragmented landscape with little centralized guidance.
What actually changed
The FDA's shortage delisting did not ban compounded semaglutide outright. It eliminated the blanket exemption that had allowed 503A retail compounding pharmacies and 503B outsourcing facilities to produce the drug at commercial scale without demonstrating a specific patient need. What remains permissible are 503A compoundswritten for patients with a documented clinical reason the branded drug cannot serve — such as a confirmed allergy to an inactive ingredient — and, separately, personalized dosing formulations that differ meaningfully from the commercially available product. The latter category has become the principal legal lifeline for platforms still operating in this space.
Which platforms are still shipping
Based on publicly available platform disclosures and service-status pages reviewed through mid-April 2026, a small number of providers continue to fulfill compounded semaglutide orders. Hims & Hers paused new compounded semaglutide prescriptions in March 2026 following an FDA warning letter but has signaled it is evaluating a modified-formulation pathway. Ro has similarly suspended new starts. Among platforms still actively shipping, Mochi Health and several smaller direct-to-patient providers have continued fulfillment, citing formulations that include additives such as B12 or alternative salt forms — arguments the FDA has not yet formally accepted or rejected as of this writing. ClinicLayer's platform tracker, updated weekly, reflects current shipping status for more than 30 providers.
The 503B outsourcing facility question
Some platforms pivoted to 503B-compounded semaglutide, which faces a stricter but slightly different regulatory timeline. The FDA issued guidance in early 2026 giving 503B facilities a wind-down period for existing orders, but that window has largely closed. Facilities that continued production past the compliance deadline now face heightened inspection risk. Patients who sourced from 503B-backed platforms should note that supply chain continuity depends heavily on whether their specific pharmacy has received or responded to an FDA observation — information that is not always disclosed proactively by the telehealth intermediary.
What this means for cost
The consolidation of legal supply has predictably moved prices upward. Based on publicly listed prices across active platforms as of April 2026, compounded semaglutide — where still available — is running between roughly $199 and $399 per month depending on dose and provider, compared to a broader range seen during peak competition in 2024. Branded Wegovy's list price remains above $1,300 per month without insurance, and insurance coverage rates have not meaningfully expanded. For patients whose income qualifies them for Novo Nordisk's patient assistance program, that remains the most cost-effective route to the branded drug. For everyone else, the gap between compounded and branded pricing is wide enough that demand for still-legal compounded options remains strong despite the regulatory pressure.
What to watch in the next 60 days
Three developments will determine whether the current partial availability holds or collapses further. First, pending federal court cases — including challenges filed by compounding pharmacy trade groups — could reinstate broader compounding rights if plaintiffs succeed in arguing the FDA delisted semaglutide prematurely given ongoing access gaps. Second, the FDA is expected to publish additional guidance clarifying which additive-based formulations qualify as meaningfully different from the branded product; that guidance could validate or effectively shut down the current workaround strategies. Third, tirzepatide's compounding status remains in active litigation, and the outcome of that parallel fight will signal how aggressively regulators intend to enforce the broader GLP-1 compounding framework. ClinicLayer will update platform shipping statuses as each of these inflection points resolves.